课题基金 / 基金详情

Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis

Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis
隐孢子虫病、弓形虫病和新孢子虫病的双重用途疗法
批准号:
9306892
负责人:
WESLEY C VAN VOORHIS
金额:
$35.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-24 至 2019-06-30

项目摘要

项目成果

WESLEY C VAN VOORHIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): New drugs are urgently needed for cryptosporidiosis and toxoplasmosis for human and domestic livestock use. Cryptosporidiosis causes wasting diarrhea in humans and calves. Toxoplasmosis is an important cause of fetal malformations and abortions in humans and domestic livestock. In addition, an effective drug is also needed for veterinary use for neosporosis, the cause of epidemic abortions in livestock. This project follows on our successful hit-to-lead drug development project, targeting protozoan Calcium Dependent Protein Kinases (CDPKs). We now have two promising pre-clinical drug candidates that show activity in mouse models of cryptosporidiosis, toxoplasmosis and neosporosis, and thus are of great potential value for both veterinary and human health. The goal of this project will be to conduct efficacy, pharmacokinetic (PK), and toxicity testing of our novel therapeutics in agriculturally-important domestic animals (cattle and sheep) to show efficacy for animal diseases and to also gather information for the preclinical drug package for human use. We will scale-up the compounds to the near kilogram quantity, test their efficacy in sheep models of toxoplasmosis and neosporosis, and in a calf model of cryptosporidiosis. In the end of this project, the goal is to have a preclinical drug candidate and one or two backups to advance to final preclinical testing and IND/NADA registration for veterinary and human use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of Lead BKIs for Cryptosporidiosis Therapy
  • 批准号:
    10540344
  • 项目类别:
  • 资助金额:
    $80.4万
  • 财政年份:
    2021
  • 负责人:
    WESLEY C VAN VOORHIS
  • 依托单位:
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis
  • 批准号:
    10204654
  • 项目类别:
  • 资助金额:
    $70.13万
  • 财政年份:
    2021
  • 负责人:
    WESLEY C VAN VOORHIS
  • 依托单位:
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis
  • 批准号:
    10372218
  • 项目类别:
  • 资助金额:
    $63.4万
  • 财政年份:
    2021
  • 负责人:
    WESLEY C VAN VOORHIS
  • 依托单位:
Optimization of Lead BKIs for Cryptosporidiosis Therapy
  • 批准号:
    10090142
  • 项目类别:
  • 资助金额:
    $83.45万
  • 财政年份:
    2021
  • 负责人:
    WESLEY C VAN VOORHIS
  • 依托单位:
海外基金